Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sonoma Biotherapeutics, Inc.

Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Tickers REGN
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.